Skip to main content
iDNA Genomics Public Ltd logo

iDNA Genomics Public Ltd — Investor Relations & Filings

Ticker · IDNA ISIN · CY0109800710 LEI · 2549006HMJWPY9CIB812 CSE Human health and social work activities
Open in API
Filings indexed 80 across all filing types
Latest filing 2025-12-31 Director's Dealing
Country CY Cyprus
Listing CSE IDNA

About iDNA Genomics Public Ltd

https://idnagenomics.com/en/

iDNA Genomics Public Ltd is a biotechnology company specializing in genetic analysis and precision medicine. It develops and provides DNA tests focused on three main areas: pharmacogenetics, which analyzes how genes affect a person's response to drugs; preventive medicine, which screens for genetic predispositions to diseases; and wellness genomics, which informs personalized nutrition and exercise plans. The company's product portfolio includes tests for cardiovascular health and responses to central nervous system medications. Genetic analysis is performed in its certified laboratories, supported by a proprietary bioinformatics platform and an artificial intelligence database that is continuously updated with recent scientific data to ensure accuracy. iDNA Genomics also provides the myEMR online platform for individuals and healthcare professionals to register test kits and manage genetic results.

Recent filings

Filing Released Lang Actions
Director's Dealing 2025
Director's Dealing Classification · 100% confidence The document is a standard notification form for transactions by persons discharging managerial responsibilities (PDMRs) under the EU Market Abuse Regulation (MAR). It explicitly details a sale of ordinary shares by an entity controlled by a director of the issuer (IDNA Genomics Public Ltd). This falls directly under the definition of 'Director's Dealing' (DIRS).
2025-12-31 English
Regulatory Filings 2025
Regulatory Filings Classification · 95% confidence The document is an official announcement from iDNA Genomics Public Ltd to the Cyprus Stock Exchange regarding the implementation and progress of its business plan for 2025. It details operational developments, regulatory compliance, and international expansion strategies. Since it is a general corporate update provided to a regulatory body that does not fit into specific categories like financial results (ER/IR) or board changes (MANG), it falls under the 'Regulatory Filings' category.
2025-12-23 Greek (modern)
Capital/Financing Update 2025
Capital/Financing Update Classification · 95% confidence The document is an official announcement from iDNA Genomics Public Ltd regarding the conversion terms and dates for its convertible bonds. It details the conversion price, the conversion ratio, and the procedural requirements for bondholders to exercise their rights. This falls under capital structure and financing updates, specifically related to the conversion of debt instruments into equity, which aligns with the 'Capital/Financing Update' category.
2025-12-22 Greek (modern)
Director's Dealing 2025
Director's Dealing Classification · 100% confidence The document is a standard notification form for transactions by persons discharging managerial responsibilities (PDMRs) under the EU Market Abuse Regulation (MAR). It explicitly details a sale of ordinary shares by an entity controlled by a director of the issuer (IDNA Genomics Public Ltd). This falls directly under the definition of 'Director's Dealing' (DIRS).
2025-12-16 English
Director's Dealing 2025
Director's Dealing Classification · 100% confidence The document is a standard notification form for transactions by persons discharging managerial responsibilities (PDMRs) under the EU Market Abuse Regulation (MAR). It explicitly details a sale of ordinary shares by an entity controlled by a director of the issuer (IDNA Genomics Public Ltd). This falls directly under the definition of 'Director's Dealing'.
2025-11-26 English
Director's Dealing 2025
Director's Dealing Classification · 100% confidence The document is a standard notification form for transactions by persons discharging managerial responsibilities (PDMRs) under the EU Market Abuse Regulation (MAR). It explicitly details a sale of shares by a company controlled by a director. This matches the definition for 'Director's Dealing' (DIRS).
2025-11-24 English

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.